| Code | CSB-MP004847HU |
| Abbreviation | Recombinant Human CCR8 protein-VLPs (Active) |
| MSDS | |
| Size | $558 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
CCR8 has emerged as a compelling immunotherapy target due to its selective expression on tumor-infiltrating regulatory T cells, making it a focus of therapeutic antibody development in immuno-oncology. This recombinant human CCR8 construct spans the full-length sequence (aa 1–355) and is presented on virus-like particles derived from mammalian cells, preserving the multi-pass transmembrane topology and native conformational epitopes that are critical for GPCR targets. Functional ELISA confirms binding to an anti-CCR8 recombinant antibody with an EC50 of 11.13–17.29 ng/ml when immobilized at 5 μg/ml, providing a suitable basis for blocking antibody screening, therapeutic antibody epitope mapping, and ligand-receptor interaction studies via ELISA, SPR, or BLI. Endotoxin levels below 1.0 EU/μg, combined with the VLP format that maintains conformational integrity, support use in drug discovery workflows targeting CCR8-mediated immune suppression in the tumor microenvironment.
Applications : Drug related studies
Review: CCR8 is a multi-pass transmembrane protein, and expressing only its extracellular domain can disrupt its conformational epitopes, resulting in the loss of some antigenic epitopes. Your company has developed this full-length protein with good biological activity and immunogenicity. It will be very helpful for our company\'s subsequent development of antibody drugs.
By Anonymous
I notice you provide CCR8 nanodiscs, could you inform me about the exposure of both the intracellular and extracellular domain? We would like to screen a panel of antibodies with potency for detecting either intracellular or extracellular epitopes of this target.
For a VLP, per definition the intracellular domain is not exposed, as I am aware of, which is not ideal for our purpose.
VLP only exposes the extracellular domain, and the intracellular domain is not exposed in the envelope, which is mainly to screen and recognizes the extracellular epitopes, so VLP may not be suitable for customers' experiments. The customer would like to screen a group of antibodies that can detect the intracellular or extracellular site of the target. We recommend CSB-CF004847HU ,which express full-length protein by a cell-free expression system, but no activity test was performed and it is not guaranteed to identify the endogenous sample. Or it is suggested that the customer select the intracellular or extracellular domain sequence of the target protein for recombinant expression, and screen the antibodies that identify the intracellular or cellular epitopes of the target, but can not guarantee the recognition of endogenous samples.